Wall Street brokerages expect that Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) will announce earnings per share (EPS) of ($0.35) for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Adaptimmune Therapeutics’ earnings. The lowest EPS estimate is ($0.40) and the highest is ($0.29). Adaptimmune Therapeutics reported earnings of ($0.48) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 27.1%. The firm is scheduled to announce its next earnings results on Thursday, August 1st.

According to Zacks, analysts expect that Adaptimmune Therapeutics will report full-year earnings of ($1.17) per share for the current fiscal year, with EPS estimates ranging from ($1.34) to ($0.94). For the next year, analysts expect that the company will report earnings of ($1.16) per share, with EPS estimates ranging from ($1.45) to ($0.83). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Adaptimmune Therapeutics.

Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its earnings results on Monday, May 6th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.28) by $0.04. Adaptimmune Therapeutics had a negative return on equity of 45.03% and a negative net margin of 161.09%.

A number of equities research analysts have recently issued reports on the company. Zacks Investment Research upgraded DLH from a “sell” rating to a “hold” rating in a research note on Tuesday, July 9th. Leerink Swann lowered Adaptimmune Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.15 price objective on the stock. in a report on Tuesday, May 7th. Roth Capital started coverage on Tcr2 Therapeutics in a report on Friday, May 31st. They set a “neutral” rating and a $16.00 target price on the stock. Svb Leerink lowered Intersect ENT from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $41.00 to $29.00 in a report on Tuesday, May 7th. Finally, Citigroup set a $14.00 target price on Coty and gave the stock a “hold” rating in a report on Thursday, May 30th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Adaptimmune Therapeutics has an average rating of “Buy” and an average price target of $6.59.

Hedge funds have recently made changes to their positions in the stock. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its position in shares of Adaptimmune Therapeutics by 8.7% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 28,621 shares of the biotechnology company’s stock worth $123,000 after buying an additional 2,280 shares during the last quarter. Raymond James & Associates lifted its position in shares of Adaptimmune Therapeutics by 59.0% during the 4th quarter. Raymond James & Associates now owns 22,906 shares of the biotechnology company’s stock worth $132,000 after buying an additional 8,498 shares during the last quarter. Squarepoint Ops LLC bought a new stake in shares of Adaptimmune Therapeutics during the 4th quarter worth $622,000. Deutsche Bank AG lifted its position in shares of Adaptimmune Therapeutics by 1,681,328.6% during the 4th quarter. Deutsche Bank AG now owns 117,700 shares of the biotechnology company’s stock worth $676,000 after buying an additional 117,693 shares during the last quarter. Finally, Rathbone Brothers plc lifted its position in shares of Adaptimmune Therapeutics by 27.9% during the 1st quarter. Rathbone Brothers plc now owns 285,722 shares of the biotechnology company’s stock worth $1,229,000 after buying an additional 62,292 shares during the last quarter. Institutional investors and hedge funds own 66.30% of the company’s stock.

NASDAQ ADAP traded up $0.17 during trading on Friday, hitting $3.18. The stock had a trading volume of 239,323 shares, compared to its average volume of 191,255. Adaptimmune Therapeutics has a 12 month low of $2.94 and a 12 month high of $14.54. The firm has a market cap of $315.12 million, a P/E ratio of -3.31 and a beta of 1.63. The company has a debt-to-equity ratio of 0.12, a current ratio of 8.55 and a quick ratio of 8.55. The company has a 50-day moving average price of $3.60.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.

Featured Story: P/E Growth (PEG)

Get a free copy of the Zacks research report on Adaptimmune Therapeutics (ADAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.